Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
Gut and Liver
;
: 721-727, 2017.
Article
in English
| WPRIM
| ID: wpr-175157
ABSTRACT
BACKGROUND/AIMS:
Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia.METHODS:
Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21; 1a, n=5) and four patients were genotype 2a/2b. Among 21 patients with genotype 1b, Y93H resistance-associated variants (RAVs) were detected in three patients (14.3%). We evaluated sustained virologic response (SVRs) at 12 weeks, as well as relapse and safety.RESULTS:
Five patients with genotype 1a and three patients with genotype 1b (RAV positive) received ledipasvir/sofosbuvir for 12 weeks. SVR12 rate was 100% (8/8). Eleven patients with genotype 1b were treatment-naïve and received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 91% (10/11). One patient experienced viral breakthrough without RAV at 12 weeks. Seven treatment-experienced patients with genotype 1b received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 85.7% (6/7). One patient experienced viral breakthrough with RAV (L31M, Y93H) at 12 weeks. Four patients with genotype 2a/2b received sofosbuvir plus ribavirin for 12 weeks. SVR12 rate was 100% (4/4). No serious adverse event-related discontinuations were noted.CONCLUSIONS:
New direct acting antiviral treatment achieved high SVRs rates at 12 weeks in CHC patients with hemophilia without serious adverse events.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Recurrence
/
Ribavirin
/
Comorbidity
/
Hepatitis C
/
Hepatitis C, Chronic
/
Sofosbuvir
/
Genotype
/
Hemophilia A
/
Hepatitis, Chronic
Limits:
Humans
Language:
English
Journal:
Gut and Liver
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS